<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00784511</url>
  </required_header>
  <id_info>
    <org_study_id>8095</org_study_id>
    <secondary_id>ADA 7-08-CR-27</secondary_id>
    <nct_id>NCT00784511</nct_id>
  </id_info>
  <brief_title>Vitamin D, Glucose Control and Insulin Sensitivity in African-Americans</brief_title>
  <official_title>Vitamin D, Glucose Control and Insulin Sensitivity in African-Americans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tufts University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      North American blacks tend to have low blood levels of vitamin D because pigmentation blocks&#xD;
      vitamin D production in the skin. They also have higher rates of developing type 2 diabetes&#xD;
      and higher rates of complications from the disease compared with whites. Although there is&#xD;
      compelling evidence that adequate vitamin D may reduce the risk for type 2 diabetes in&#xD;
      whites, recent evidence from a national survey demonstrated an association of vitamin D with&#xD;
      diabetes in whites but not in blacks. However, the central hypothesis of this study is that&#xD;
      providing enough supplemental vitamin D to blacks (raising their blood levels higher than&#xD;
      that of most participants in the survey) will improve blood measures related to diabetes&#xD;
      risk. The proposed study is a 12-week randomized, double-blind, placebo-controlled experiment&#xD;
      designed to examine the effect of vitamin D supplementation (100 μg/d ) on insulin secretion,&#xD;
      insulin sensitivity and glucose control in pre-diabetic black men and women aged 40 and&#xD;
      older.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin secretion rate</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin sensitivity index</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>2-hr post load glucose</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1 vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin D3, 4000 IU/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cholecalciferol</intervention_name>
    <description>4000 IU/d</description>
    <arm_group_label>1 vitamin D3</arm_group_label>
    <other_name>vitamin D3</other_name>
    <other_name>vitamin D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>microcrystalline cellulose</intervention_name>
    <description>1/d</description>
    <arm_group_label>2</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  African-American by self designation&#xD;
&#xD;
          -  Glucose intolerance defined as FPG ≥ 100 mg/dl or A1c ≥ 5.8%&#xD;
&#xD;
          -  BMI 25.0-39.9&#xD;
&#xD;
          -  Age 40 or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Medical Conditions&#xD;
&#xD;
          -  Diabetes potentially requiring pharmacotherapy, defined as A1c &gt; 7%&#xD;
&#xD;
          -  Uncontrolled thyroid disease&#xD;
&#xD;
          -  Current parathyroid, liver or kidney disease&#xD;
&#xD;
          -  Renal stone within 5 years&#xD;
&#xD;
          -  Sarcoidosis, current pancreatitis, active tuberculosis, hemiplegia, gout&#xD;
&#xD;
          -  Inflammatory bowel disease, colostomy, malabsorption&#xD;
&#xD;
          -  Cancer other than basal cell skin cancer within 5 years&#xD;
&#xD;
          -  Uncontrolled arrhythmia in past year&#xD;
&#xD;
          -  Albinism or other condition associated with reduced skin pigmentation&#xD;
&#xD;
          -  Pregnancy over the last 1 year&#xD;
&#xD;
          -  Intent to become pregnant&#xD;
&#xD;
          -  Menopause onset within 1 year&#xD;
&#xD;
          -  Any other unstable medical condition Laboratory Tests&#xD;
&#xD;
          -  Fasting plasma glucose &lt; 100&#xD;
&#xD;
          -  Hemoglobin A1c &gt; 7%&#xD;
&#xD;
          -  Laboratory evidence of liver disease (e.g. AST &gt; 70 U/L or ALT &gt; 72 IU/L)&#xD;
&#xD;
          -  Laboratory evidence of kidney disease (e.g. estimated glomerular filtration rate &lt; 60&#xD;
             ml/min/1.73 m2).&#xD;
&#xD;
          -  Elevated spot urine calcium to creatinine ratio &gt; 0.38 mg/dl*&#xD;
&#xD;
          -  Abnormal serum calcium (serum calcium &gt; 10.5 mg/dl)&#xD;
&#xD;
          -  Anemia (Hematocrit &lt; 36% in men, &lt;33% in women) Medications (use in past three months)&#xD;
&#xD;
          -  Estrogen or testosterone&#xD;
&#xD;
          -  Prescription vitamin D&#xD;
&#xD;
          -  Lithium&#xD;
&#xD;
          -  Oral corticosteroids&#xD;
&#xD;
          -  Anti-seizure medications&#xD;
&#xD;
          -  Unstable doses of psychotropics or phenothiazines&#xD;
&#xD;
          -  Cholestyramine Supplements (current use - may discontinue after screening)&#xD;
&#xD;
          -  Vitamin D supplements, cod liver oil, calcium supplements Other&#xD;
&#xD;
          -  Body mass index less &lt;25 or &gt; 39.9&#xD;
&#xD;
          -  Consumption of more than 14 alcoholic drinks per week&#xD;
&#xD;
          -  Inability to attend all three study visits as scheduled&#xD;
&#xD;
          -  Inability to provide written informed consent&#xD;
&#xD;
          -  age &lt; 40 years&#xD;
&#xD;
          -  not African-American (by self-designation)&#xD;
&#xD;
          -  Participation in another research intervention study&#xD;
&#xD;
               -  corresponds to a 24-hour urinary calcium excretion &gt; 400 mg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>November 3, 2008</study_first_submitted>
  <study_first_submitted_qc>November 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2008</study_first_posted>
  <last_update_submitted>November 13, 2014</last_update_submitted>
  <last_update_submitted_qc>November 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tufts University</investigator_affiliation>
    <investigator_full_name>Susan Harris</investigator_full_name>
    <investigator_title>Scientist I</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>vitamin D</keyword>
  <keyword>African Americans</keyword>
  <keyword>overweight</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>glucose control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

